Kriya Therapeutics
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing accessible gene therapies for prevalent chronic diseases. By utilizing a vertically integrated model that encompasses design, development, and in-house manufacturing, Kriya aims to make transformative treatments more scalable and affordable. The company is advancing a diversified pipeline targeting conditions in ophthalmology, metabolic disease, and neurology.
Products & Team
Integrated Gene Therapy Development Platform (SIRVE™ & STRIPE™)
Kriya's core offering consists of two proprietary technology platforms that power its pipeline of investigational gene therapies. The SIRVE™ platform uses computational tools and machine learning for the rational design of adeno-associated virus (AAV) vectors to optimize their therapeutic properties. This is paired with the STRIPE™ platform, an innovative manufacturing system designed for scalable, high-efficiency, and cost-effective production of gene therapies.
The integrated platform addresses the core challenges of gene therapy development by enabling the efficient design of novel therapies and providing a scalable, cost-effective manufacturing solution. This approach is intended to accelerate timelines and make gene therapies commercially viable for chronic diseases affecting millions of people.
Kriya addresses the need for durable, one-time treatments for chronic diseases that currently require lifelong management, frequent interventions, or have limited effective therapeutic options. The goal is to provide a lasting solution that resolves the underlying biology of the disease.